Several other research firms have also issued reports on TH. Mackie lowered their price target on shares of Theratechnologies from C$5.30 to C$4.40 in a research report on Wednesday, July 6th. Canaccord Genuity lowered their price target on shares of Theratechnologies from C$4.25 to C$3.75 in a research report on Thursday, July 7th.
Theratechnologies (TSE:TH) opened at 2.90 on Tuesday. Theratechnologies has a 52-week low of $1.26 and a 52-week high of $3.74. The company has a 50-day moving average of $2.66 and a 200 day moving average of $2.48. The company has a market cap of $191.20 million and a PE ratio of 725.00.
Theratechnologies Company Profile
Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs in metabolic disorders to promote healthy ageing among human immunodeficiency virus (HIV) patients. The Company’s product, EGRIFTA (tesamorelin for injection), is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.